Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 21, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.

Cristiana Bellan1, Lazzi Stefano, De Falco Giulia

  • 1Department of Human Pathology and Oncology, University of Siena, Siena, Italy.

Hematological Oncology
|August 12, 2009
PubMed
Summary

Distinguishing aggressive Burkitt Lymphoma (BL) from diffuse large B-cell lymphoma (DLBCL) is crucial for treatment. This review details methods to differentiate these aggressive B-cell lymphomas, including intermediate cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: EBV strategies to counteract the immune response.

Frontiers in immunology·2026
Same author

Virtual Evaluation of Hematoxylin & Eosin via Digital Pathology Survey (VEED) Project: Results from a Non-Inferiority Study of a Tabs-Based Staining Method.

Diagnostics (Basel, Switzerland)·2026
Same author

Correction: P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma.

Cell death & disease·2026
Same author

An oncogenic role for EBV-encoded BILF1 in nasopharyngeal carcinoma.

The Journal of pathology·2026
Same author

Hit-and-run hypothesis: revisiting the impact of EBV in malignancies.

Frontiers in immunology·2026
Same author

Immune disparities in the TME of EBV+ and EBV- BL: role of reactive oxygen species generation pathways and platelet activation.

Blood advances·2026

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Burkitt Lymphoma (BL) is an aggressive B-cell non-Hodgkin's lymphoma characterized by rapid proliferation and c-MYC gene deregulation.
  • Distinguishing BL from diffuse large B-cell lymphoma (DLBCL) presents diagnostic challenges, particularly in adults with intermediate features.

Purpose of the Study:

  • To review current diagnostic approaches for differentiating BL from DLBCL.
  • To address the classification of B-cell lymphomas with intermediate features between BL and DLBCL.

Main Methods:

  • Utilizing a comprehensive panel of antibodies for immunophenotypic analysis.
  • Employing cytogenetic and molecular diagnostic techniques.
  • Reviewing WHO classification criteria for lymphoid tumors.

Related Experiment Videos

Last Updated: Jun 21, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Main Results:

  • Diagnostic challenges arise from cases with morphological, immunophenotypic, and cytogenetic features intermediate between BL and DLBCL.
  • Accurate differentiation is critical as BL and DLBCL require distinct management strategies.

Conclusions:

  • Current practical approaches involve integrated diagnostic methods to classify aggressive B-cell lymphomas.
  • The WHO classification now includes a provisional category for unclassifiable B-cell lymphomas with intermediate features.